“We expect upward earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. These could come from positive news flow for Revance’s key programs in development. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $50 and Overweight rating.”
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -8.0% and a 38.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
Revance Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $49.
Based on Revance Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $34.08 million. In comparison, last year the company had a GAAP net loss of $26.87 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.